Endoscopic evaluation of the gastroduodenal mucosa to determine the safety of short-term concurrent administration of meloxicam and dexamethasone in healthy dogs

Boston, Sarah E.; Moens, Noël M. M.; Kruth, Stephen A.; Southorn, Erin

doi:10.2460/ajvr.2003.64.1369

Cited by 60 publications

(50 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meloxicam is a selective COX-2 inhibitor, and the safety of meloxicam use in dogs has been previously described [10]. In the present study, there were fewer gastric mucosal adverse effects of combined meloxicam and prednisolone than in a previous study, in which the short-term concurrent administration of meloxicam (0.1 mg/kg, PO, q 24 hr) and dexamethasone (0.25 mg/kg, SC, q 12 hr) for 3 days caused more gastric erosions, but not gastric ulcers, than meloxicam alone [4]. Dexamethasone is thought to have more ulcerogenic power than prednisolone, and some reports have shown that a non-ulcerogenic dose of dexamethasone delayed gastric ulcer healing in animals [26,27].…”

Section: Disccusioncontrasting

confidence: 42%

The Interaction between Orally Administered Non-Steroidal Anti-Inflammatory Drugs and Prednisolone in Healthy Dogs

Narita

Sato

Motoishi

et al. 2007

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

ABSTRACT. The interaction between oral non-steroidal anti-inflammatory drugs (NSAIDs) and prednisolone administered concurrently for 30 days was studied in 18 healthy dogs divided into 3 groups of 6 dogs each: a drug-free negative control group (NC group) given 2 gelatin capsules; a group given meloxicam (0.1 mg/kg) and prednisolone (0.5 mg/kg) (MP group); and a group given a reduced dosage of ketoprofen (0.25 mg/kg, PO) and prednisolone (0.5 mg/kg, PO) (KP group). The dogs were periodically monitored by physical examinations, blood analyses, endoscopic examinations, fecal occult blood tests, renal function tests [effective renal plasma flow (ERPF) and glomerular filtration rate (GFR)], urinalyses [urinary sediments, and urinary micro-albumin to creatinine ratio (UAlb/Cre)], urinary enzyme indices, and haemostatic function tests [buccal mucosa bleeding time (BMBT), cuticle bleeding time (CBT)]. Significant changes were observed in the KP group, including a decrease of ERPF and GFR, an increased UAlb/Cre ratio, prolonged BMBT and CBT, as well as the presence of more severe grades of endoscopic lesions and fecal occult blood. In both the MP and KP groups, abnormal enzymuria with exfoliation of renal tubular epithelial cells in the urine was found. However, no significant changes in any of the other tests were observed in the MP group compared with the NC group. These findings suggest that the combination of NSAIDs, even selective COX-2 inhibitors, with prednisolone may be contraindicated due to the potential for serious adverse effects on the kidneys, the platelets, and the gastrointestinal tract.

show abstract

Section: Disccusioncontrasting

confidence: 42%

The Interaction between Orally Administered Non-Steroidal Anti-Inflammatory Drugs and Prednisolone in Healthy Dogs

Narita

Sato

Motoishi

et al. 2007

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

show abstract

“…Meloxicam is considered to be a COX-2 preferential (Smecuol et al, 2001;Plumb, 2002;Jones et al, 2002;Boston et al, 2003), and spare COX-1 activity as confirmed by in vitro and in vivo studies (Engelhardt et al, 1996a;Engelhardt et al, 1996b;Kay-Mugford et al, 2000;Jones et al, 2002). The relative selectivity of meloxicam for COX-2 may contribute to an improved tolerability profile compared with less selective NSAIDs (Vane, 1995;Fresno et al, 2005), resulting in reduced mucosal injury after its use (Smecuol et al, 2001).…”

Section: Introductionmentioning

confidence: 87%

“…It can be summarized that the therapeutic anti-inflammatory, analgesic, and antipyretic effects are due to the inhibition of COX-2. The undesirable gastrointestinal adverse effects, nephrotoxicity and coagulation disorders are believed to result from inhibition of COX-1 (Vane and Botting, 1998;Steinmeyer, 2000;Lichtenberger, 2001;Jones et al, 2002;Boston et al, 2003). Inhibition of COX-1 with a resultant decrease in endogenous prostaglandins critical to mucosal defence, especially PGE 1 (prostaglandin E 1 ), PGE 2 (prostaglandin E 2 ) and PGI 2 (prostaglandin I 2 ), is thought to be the most important mechanism of action of NSAIDs (Bowersox et al, 1996;Rich and Scheiman, 2000;Tomlinson and Blikslager, 2003).…”

Section: Introductionmentioning

confidence: 96%

Effect of meloxicam and meloxicam with misoprostol on serum prostaglandins and gastrointestinal permeability in healthy beagle dogs

Roškar¹,

Nemec²,

Jerin³

et al. 2011

Acta vet. (Beogr.)

View full text Add to dashboard Cite

The aim of the present study was to investigate the effect of meloxicam and meloxicam with misoprostol on prostaglandin E2 (PGE2) and prostaglandin I2 (PGI2) serum concentration, as well as on gastrointestinal permeability. NSAIDs, such as meloxicam, have gastrointestinal side effects, which are due to prostaglandins depletion and topical damage. Seven adult beagle dogs were included in the study. Three different 20 days long treatments were carried out (placebo, meloxicam and meloxicam with misoprostol). The same seven dogs participated in all three treatments. On days 1 to 10 the dogs received placebo, meloxicam or meloxicam together with misoprostol PO. Dogs were than monitored from day 11 to 20. Samples for serum PGE2 and PGI2 concentration and plasma lactulose, mannitol and sucrose concentration determination were drawn on day 0, 2, 6, 11 and 20. Lactulose/mannitol (L/M) index was calculated. Treatment with meloxicam and meloxicam with misoprostol resulted in lower PGE2 and PGI2 serum concentrations in comparison to the placebo. L/M index and sucrose plasma concentration were increased in both groups in comparison to the placebo. According to the results of the study, meloxicam has altered gastrointestinal permeability and depleted prostaglandins production. Misoprostol was shown to be an effective preventing treatment

show abstract

“…Dexamethasone has been shown inhibitory effects of angiogenesis at the ulcer margins and baseline. Administration of corticosteroids along with NSAIDs leads to the formation of gastric mucosal lesions (Boston et al, 2003). Some studies had been shown that support the theory that corticosteroids alone lead to GI mucosal injury and hemorrhage (Rohrer et al, 1999).…”

Section: Etiopathogenesis Of Gastritis and Peptic Ulcer Diseasesmentioning

confidence: 96%

Gastritis and Peptic Ulcer Diseases in Dogs: A Review

Patel¹,

Patel²,

Dixit³

et al. 2018

Int.J.Curr.Microbiol.App.Sci

View full text Add to dashboard Cite

Endoscopic evaluation of the gastroduodenal mucosa to determine the safety of short-term concurrent administration of meloxicam and dexamethasone in healthy dogs

Abstract: In healthy dogs, meloxicam appears to be safe with regard to adverse effects on the gastrointestinal tract. Concurrent administration of dexamethasone and meloxicam is more likely to cause gastric erosions than meloxicam administration alone.

Cited by 60 publications

References 31 publications

The Interaction between Orally Administered Non-Steroidal Anti-Inflammatory Drugs and Prednisolone in Healthy Dogs

The Interaction between Orally Administered Non-Steroidal Anti-Inflammatory Drugs and Prednisolone in Healthy Dogs

Effect of meloxicam and meloxicam with misoprostol on serum prostaglandins and gastrointestinal permeability in healthy beagle dogs

Gastritis and Peptic Ulcer Diseases in Dogs: A Review

Contact Info

Product

Resources

About